Navigation Links
Revolutionary Eye Cancer Treatment

A new locally applied treatment for the eye cancer retinoblastoma has been developed by scientists at St. Jude Children's Research Hospital and demonstrated// in a mouse model to cause a remarkable reduction in the size of the tumor, without causing the side effects common with standard chemotherapy. In addition the treatment also appears to be suitable for certain forms of breast, lung, prostate and colon cancer, and is simple enough for widespread use even in countries with limited resources.

A report on this work appears in the Nov. 2 issue of the journal Nature.

Retinoblastoma occurs in about 5,000 young children worldwide each year, arising from the immature retina, which is the part of the eye responsible for detecting light and color. The cancer is fatal if left untreated.

The new treatment holds promise for a simpler, more effective and less-toxic treatment for retinoblastoma that would eliminate the need for the current, complex therapy, according to senior author Michael Dyer, Ph.D., a Pew Scholar and associate member of the St. Jude Department of Developmental Neurobiology. The treatment is based on a discovery by Dyer's laboratory that overturned a widely held belief about the process of apoptosis (cell suicide) in retinoblastoma. Apoptosis is the way the body rids itself of abnormal cells that might become cancerous or cause other problems.

Until now, retinoblastoma experts thought that a mechanism called the p53 pathway triggered apoptosis in other types of cancer cells, but not in retinoblastoma. However, the St. Jude team proved not only that the p53 pathway was activated in early-stage retinoblastoma, but that excessive levels of a molecule called MDMX blocked it from triggering apoptosis in more advanced tumors. Based on this discovery, the St. Jude team used a molecule called nutlin-3 to block MDMX in retinoblastoma cells in test tube studies as well as in mouse models. The molecule was originally deve loped by Roche Pharmaceuticals (Nutley, N.J.) for a similar use against a related target called MDM2 in adult cancer cells.

The success in knocking out MDMX with nutlin-3 represents the first example of local delivery of a targeted chemotherapy drug for any childhood cancer, Dyer said.

Targeted therapy uses a customized drug to disable a specific molecule inside a growing cancer cell; local delivery is the placement of a drug at the site of disease, rather than systemic treatment. In systemic treatment, such as chemotherapy, a drug is infused into the body through a vein and then circulates, often causing toxic side effects that are especially challenging in children.

After demonstrating that nutlin-3 is effective when applied directly to the eye, the St. Jude team modified the treatment by combining this molecule with topotecan, a drug also being investigated in the treatment of retinoblastoma. Local delivery of this two-drug targeted treatment was even more effective, reducing tumor size significantly more than the most effective known combination of standard chemotherapy drugs.

"The findings suggest that this treatment not only could offer children with retinoblastoma more effective and less-toxic treatment," Dyer said. "It could also increase the chance that their vision can be preserved by eliminating the tumor and preventing its spread from the eye to the rest of the body."

The discovery that blocking MDMX releases the apoptosis response in retinoblastoma has important implications for certain forms of adult cancers as well. "Some forms of breast, lung, prostate and colon cancer are caused by abnormally large quantities of MDMX in the cells," Dyer explained. "So knocking out MDMX in those cancers might also dramatically reduce tumor size. And administering the drug directly to the site of the tumor could make the treatment especially effective while avoiding the toxicity caused by systemic exposure." T his could mean the eventual elimination of all-body chemotherapy for certain cancers.

This work is likely to have its biggest impact on the care of children with retinoblastoma internationally, according to Dyer. Most children in the United States with retinoblastoma do not die from the disease because they benefit from early detection and advanced medical treatment. The complex treatment includes chemotherapy, radiation and laser therapy, as well as control of infections caused by treatment-related suppression of the immune system. However, most of the 5,000 children worldwide who are found to have retinoblastoma live primarily in countries with limited resources and have restricted access to medical treatment, according to Carlos Rodriguez-Galindo, M.D., an associate member of the St. Jude Oncology department.

"Today, those children do not have access to the advanced treatments available in other countries, such as the United States," Rodriguez-Galindo said, "but our new approach has the potential to make the treatment of retinoblastoma simpler and less toxic. Ideally, these treatments could be administered even in countries that cannot afford the highly complex infrastructure now required to manage children with retinoblastoma. This would mean saving many more lives and preserving more vision." Rodriguez-Galindo is a co-author of the paper.

Retinoblastoma can occur as a unilateral (one eye) or bilateral (both eyes) disease. In the case of unilateral disease, surgeons generally remove the eye that has the cancer in order to prevent the disease from spreading. However, children with bilateral retinoblastoma pose a significant challenge to physicians, who are reluctant to remove both eyes from young children, said Matthew Wilson, M.D., a surgeon in the St. Jude ophthalmology division and a co-author of the paper. In those cases, the physicians institute aggressive systemic chemotherapy to reduce the size of the tumor, followed by one of several possible therapies such as radiation or lasers to destroy the remaining cancer cells in the eye. "When successful, this therapy often saves vision," Wilson said. "Clinicians at major medical institutions generally save 70 percent of all eyes treated, even in the case of advanced disease."

Source-Eurekalert
NLA
'"/>




Related medicine news :

1. Revolutionary Simple Pregnancy Blood Test Can Save Both Mother And Child
2. Revolutionary Pill Cuts Risk of Breast Cancer
3. A Revolutionary New Treatment For Cancer Available In Australia
4. New Revolutionary Drug Could Stop the Spread of HIV
5. Revolutionary New Treatment Plan Developed For Treatment Of Unexplained Symptoms
6. Revolutionary Net To Control Malaria
7. Revolutionary Net To Control Malaria
8. Revolutionary Pill Promises Relief for Hay Fever Sufferers
9. Fibroids unlikely to Turn Cancerous
10. Virus Level could Predict Cervical Cancer Risk
11. Cancer Doctors Okays Controversial Prostate Therapy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... ... ... manicurist from Greet, S.C., wants to offer people a new way to care for their ... feet, so I know the importance of proper foot care," he said. "In order to ... , The FOOT-TRAN SYSTEM enables a user to clean and exfoliate the bottoms of his ...
(Date:3/30/2017)... ... March 30, 2017 , ... This morning, more than 275 ... their support for an independent Vaccine Safety Commission. Five of the signers of ... will hold a press conference at 9:00 AM Friday, March 31 at ...
(Date:3/29/2017)... ... ... In the United States alone, up to 36% of primary brain tumors ... brain tumors(3). Though most meningiomas are benign, metastatic brain tumors are known to grow ... options, the San Diego Gamma Knife Center offers a precision-medicine based solution ...
(Date:3/29/2017)... ... ... Grass pollen is the main cause of hay fever in the United States, with an ... runs from May to July each year; with the worst time for sufferers being June ... balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in ...
(Date:3/29/2017)... ... 2017 , ... Sublime Naturals and its founder, Kathy Heshelow, are big fans ... been used for thousands of years. , "The West has caught on, and has ... How to Use it For Your Wellness. Overcome Inflammation, Enemy of the Body. " ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... HUNTINGTON BEACH, Calif. , March 29, 2017 ... treatment have recognized remote monitoring devices like  Soberlink ... monitoring.   The consensus paper, published in early ... "feasible, practical and valuable in managing patient recovery." ... published in the Journal of Addiction Medicine, detail ...
(Date:3/29/2017)... leader in accelerated orthodontics, OrthoAccel ® Technologies, Inc. ... Manal Ibrahim , Kenji Ojima , Ivan ... microlecture presenters at the AcceleDent ® booth (#3037) ... Session, April 21-25, 2017. Orthodontists and their staff are ... a.m. On the opening morning of AAO exhibitions, Sat., ...
(Date:3/29/2017)... N.J. , March 29, 2017  Glenmark ... results for GSP 301, an investigational fixed-dose combination ... (665 mcg) administered twice-daily as a nasal spray ... rhinitis. These results are from a recently completed ... of GSP 301 combination therapy versus mometasone, olopatadine ...
Breaking Medicine Technology: